Aclaris Therapeutics Inc

ACRS remains in a Stage 2 advancing regime with higher highs and rising EMAs intact. The medium-term bias is bullish, reinforced by price above key moving averages despite exhaustion signals. Near-term, a Bullish Exhaustion pattern and RSI pullback indicate momentum is easing. Price is consolidating just above the 9/20 EMA band, making timing unfavorable now. Wait for a pullback into rising EMA support before initiating any long exposure.

• ↑ATI-2138 advanced into a proof-of-concept study for moderate-to-severe atopic dermatitis.
• ↑Piper Sandler assigns a Buy rating, signaling positive analyst sentiment on clinical data.
• ↓Q2 2026 net loss grew to $21.5M from $15.4M year-ago, straining margins.